| Literature DB >> 30830923 |
Zubair Afzal1, Gwen M C Masclee1, Miriam C J M Sturkenboom1, Jan A Kors1, Martijn J Schuemie2.
Abstract
BACKGROUND: Propensity score (PS) methods are commonly used to control for confounding in comparative effectiveness studies. Electronic health records (EHRs) contain much unstructured data that could be used as proxies for potential confounding factors. The goal of this study was to assess whether the unstructured information can also be used to construct PS models that would allow to properly deal with confounding. We used an example of coxibs (Cox-2 inhibitors) vs. traditional NSAIDs and the risk of upper gastro-intestinal bleeding as example, since this association is often confounded due to channeling of coxibs to patients at higher risk of upper gastro-intestinal bleeding.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30830923 PMCID: PMC6398864 DOI: 10.1371/journal.pone.0212999
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Episode selection.
Fig 2Flowchart showing the process of generating a propensity score model from unstructured free-text.
Baseline characteristics of initiators of selective COX-2 inhibitors or nsNSAIDs.
| Characteristics | % | |
|---|---|---|
| COX-2 initiators | nsNSAID initiators | |
| Age (mean) | 57.7 | 47.9 |
| Male | 36.5 | 43.2 |
| Female | 63.5 | 56.8 |
| Exposure to low-dose aspirin | 2.8 | 1.1 |
| Age (years) | ||
| < = 30 | 6.5 | 17.3 |
| 31–40 | 8.4 | 16.1 |
| 41–50 | 17.7 | 22.4 |
| 51–60 | 22.4 | 19.7 |
| 61–70 | 20.8 | 13.8 |
| 71–80 | 15.9 | 7.7 |
| > 80 | 8.3 | 3.0 |
| Calendar year of treatment initiation | ||
| before 2003 | 0.1 | 10.8 |
| 2003 | 1.4 | 2.0 |
| 2004 | 3.1 | 1.9 |
| 2005 | 1.6 | 1.9 |
| 2006 | 1.5 | 1.3 |
| 2007 | 2.6 | 2.3 |
| 2008 | 7.3 | 6.7 |
| 2009 | 11.5 | 12.3 |
| 2010 | 15.6 | 16.4 |
| 2011 | 22.7 | 20.6 |
| 2012 | 30.7 | 22.7 |
| 2013 | 1.9 | 1.1 |
| UGI risk factors | ||
| Use of antiplatelets | 6.3 | 3.2 |
| Use of anticoagulants | 3.2 | 1.3 |
| Use of gastroprotective agents | 23.4 | 11.8 |
| Other comorbidities | ||
| Dyspepsia | 0.2 | 0.2 |
| Smoking | 0.5 | 0.5 |
| Heart failure | 0.4 | 0.2 |
| Diabetes mellitus | 0.5 | 0.3 |
| Concomitant use of other medication | ||
| SSRIs | 4.4 | 3.3 |
| Spironolactone | 0.7 | 0.3 |
| Calcium channel blockers | 7.2 | 3.7 |
Predictive performance of different propensity models.
| Covariate filtered on frequency ≥ 100 | 95,078 | 72.27 | |
| Method 1 | Covariate filtered on frequency ≥ 1,000 | 27,619 | 72.32 |
| Method 2 | Covariate filtered on frequency ≥ 5,000 | 11,699 | 72.17 |
| Covariates filtered using Chi-square test (independent of frequency) | 3,650 | 70.59 | |
| Method 3 | Only established confounders (age, sex, and exposure to low-dose aspirin) | 111 | 66.27 |
* AUC, area under the receiver operating characteristic curve
Hazard ratios with 95% confidence intervals (CI) comparing COX-2 inhibitors with nsNSAIDs for different matching strategies and adjustments.
| None | 0.50 | 0.18–1.36 | |
| None | 0.36 | 0.11–1.16 | |
| Sex | 0.35 | 0.11–1.18 | |
| Sex, Aspirin | 0.36 | 0.11–1.18 | |
| None | 0.42 | 0.13–1.38 | |
| Age | 0.36 | 0.10–1.22 | |
| Sex | 0.39 | 0.12–1.30 | |
| Age, Sex | 0.35 | 0.16–1.25 | |
| Sex, Aspirin | 0.39 | 0.12–1.32 | |
| None | 0.42 | 0.13–1.39 | |
| Age | 0.32 | 0.09–1.09 | |
| Sex | 0.43 | 0.13–1.42 | |
| Age, Sex | 0.31 | 0.09–1.08 | |
| Sex, Aspirin | 0.43 | 0.13–1.42 | |
| Age, Sex, Aspirin | 0.31 | 0.09–1.10 |